VJHemOnc is committed to improving our service to you

EHA 2020 | TRANSCEND-CLL-004: lisocabtagene maraleucel in CLL

VJHemOnc is committed to improving our service to you

Tanya Siddiqi

Tanya Siddiqi, MD, of City of Hope, Duarte, CA, discusses results from the Phase I/II TRANSCEND-CLL-004 (NCT03331198) study, evaluating the safety and efficacy of the Juno CAR T-cell, lisocabtagene maraleucel, in chronic lymphocytic leukemia (CLL) patients pre-treated with a BTK inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter